Diagnosing and Managing Factor V Leiden

Diagnostic Testing Methods

The American College of Medical Genetics recommends diagnosing Factor V Leiden using either direct DNA-based genotyping or a modified factor V Leiden-specific functional assay, with DNA testing required for confirmation and to distinguish heterozygotes from homozygotes 1
Direct DNA-based genotyping detects the R506Q mutation in the F5 gene and is the gold standard, providing definitive identification of heterozygous versus homozygous status 1, 2
Modified functional assay provides reliable differentiation between heterozygotes and homozygotes with minimal interference from anticoagulants or lupus anticoagulant 2, 3

Patients under 50 with any venous thrombosis should be tested, as this scenario has the highest diagnostic yield 1, 4
Venous thrombosis in unusual sites, such as hepatic, mesenteric, or cerebral veins, is an indication for testing 1, 4
Recurrent venous thrombosis at any age is a strong indication for testing 1, 4
Venous thrombosis with a strong family history of thrombotic disease is an indication for testing 1, 4
Women with recurrent pregnancy loss, unexplained severe preeclampsia, placental abruption, intrauterine growth retardation, or stillbirth should be considered for testing 1, 4

A comprehensive thrombophilia panel should include testing for prothrombin G20210A mutation, plasma homocysteine levels, functional assays for protein C, protein S, and antithrombin III, and lupus anticoagulant and anticardiolipin antibodies 6, 7

The American College of Medical Genetics recommends that heterozygous Factor V Leiden carriers typically receive standard duration anticoagulation (3-6 months) after a first VTE, as heterozygosity alone does not significantly increase recurrence risk 5
Homozygous Factor V Leiden carriers should be considered for lifetime anticoagulation after any thrombotic event due to substantially elevated recurrence risk 2, 8
Compound heterozygotes for Factor V Leiden and prothrombin 20210A mutation have high recurrence risk and should be considered for extended anticoagulation 2, 8